Sk Biopharmaceuticals Co Ltd (326030) — Financial Flexibility Index
Sk Biopharmaceuticals Co Ltd (326030) has a Financial Flexibility Index of 0.05x as of March 2026. Free cash flow of ₩20.86 Billion (operating CF ₩17.92 Billion minus capex ₩2.94 Billion) represents 0% of total liabilities (₩388.37 Billion). Check Sk Biopharmaceuticals Co Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Sk Biopharmaceuticals Co Ltd Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Sk Biopharmaceuticals Co Ltd across 10 annual periods. For the full cash flow conversion analysis, see 326030 cash generation efficiency.
Annual Financial Flexibility Index for Sk Biopharmaceuticals Co Ltd (2016–2025)
Year-by-year free cash flow to debt coverage for Sk Biopharmaceuticals Co Ltd. Explore Sk Biopharmaceuticals Co Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.55x | ₩205.84 Billion | ₩176.33 Billion | ₩372.04 Billion | ▲ +136.4% |
| 2024 | 0.23x | ₩108.32 Billion | ₩94.90 Billion | ₩462.83 Billion | ▲ +203.5% |
| 2023 | -0.23x | ₩-90.95 Billion | ₩-94.20 Billion | ₩402.22 Billion | ▲ +49.3% |
| 2022 | -0.45x | ₩-155.01 Billion | ₩-159.92 Billion | ₩347.68 Billion | ▼ -0.4% |
| 2021 | -0.44x | ₩-88.56 Billion | ₩-92.87 Billion | ₩199.46 Billion | ▲ +73.1% |
| 2020 | -1.65x | ₩-199.70 Billion | ₩-210.73 Billion | ₩121.17 Billion | ▼ -272.5% |
| 2019 | -0.44x | ₩-67.29 Billion | ₩-81.33 Billion | ₩152.10 Billion | ▲ +88.3% |
| 2018 | -3.79x | ₩-139.85 Billion | ₩-141.28 Billion | ₩36.91 Billion | ▼ -100.3% |
| 2017 | -1.89x | ₩-96.70 Billion | ₩-98.34 Billion | ₩51.12 Billion | ▼ -117.7% |
| 2016 | -0.87x | ₩-40.14 Billion | ₩-48.94 Billion | ₩46.21 Billion | — |